Office Of New Drugs' Kweder Will Represent FDA At Vioxx Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Acting Director Sandra Kweder. MD, will represent FDA at the Senate Finance Committee hearing on the Vioxx withdrawal Nov. 18
You may also be interested in...
COX-2 Advisory Committee Review Will Include New Celebrex Safety Data
Committee will also “explore ways of further evaluation” of the safety of Pfizer’s Bextra and COX-2s approved in Europe, such as Merck’s Arcoxia. FDA also expects discussion of broader NSAID category, at least for “context.”
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said